Core Viewpoint - American Rebel Holdings, Inc. has successfully met the Nasdaq Listing Rule 5550(b)(1) by achieving stockholders' equity of $3,378,257, thus remaining compliant and listed on The Nasdaq Capital Market [1][2]. Compliance Confirmation - The Nasdaq Hearings Panel confirmed compliance on November 21, 2025, following the Company's filing of its Quarterly Report on Form 10-Q for the period ended September 30, 2025 [2][5]. - The compliance determination was based on the Company's stockholders' equity exceeding the required $2.5 million threshold [2][5]. CEO Commentary - The CEO of American Rebel expressed that the compliance notice is a significant milestone for the Company and its stockholders, emphasizing the importance of a Nasdaq listing for liquidity and investor base expansion [3]. - The CEO acknowledged the support from Nasdaq, strategic partners, and stockholders during the compliance process, indicating a focus on long-term value creation moving forward [3]. Monitoring Period - Following the compliance confirmation, the Company will enter a mandatory one-year monitoring period, during which any future non-compliance will lead to immediate delisting without additional cure periods [5][6]. Improvement in Stockholders' Equity - The Company has shown significant improvement in stockholders' equity, moving from a deficit of approximately $(8.0) million as of March 31, 2025, to a positive equity of $3,378,257 by September 30, 2025, reflecting an improvement of roughly $11.4 million [11]. - This improvement is attributed to a series of strategic initiatives executed throughout 2025 to strengthen the balance sheet [7][8]. Company Overview - American Rebel Holdings, Inc. is a patriotic lifestyle brand that has expanded from designing and marketing branded safes to include products like American Rebel Light Beer, apparel, and accessories [9]. - The Company aims to grow within the premium light lager segment across the United States, leveraging experienced distribution partners [9].

Core Insights - Applied Digital successfully completed the second phase (50 MW) of its Polaris Forge 1 AI Factory Campus, bringing the total energized capacity to 100 MW [1][2][3] - The company is part of a larger 400 MW deployment for CoreWeave under long-term lease agreements, indicating strong demand for AI infrastructure [2][4] - The timely delivery of infrastructure aligns with the increasing demand for AI compute, positioning Applied Digital as a leading player in the AI infrastructure market [3][4] Company Performance - The completion of the first 100 MW building reflects the company's engineering discipline and execution reliability, meeting customer expectations for high-density systems [4] - Applied Digital has secured approximately $5 billion in leases with a U.S.-based Investment Grade Hyperscaler, raising total contracted revenue to around $16 billion across both campuses [4][5] - The company focuses on delivering high-density, production-scale AI infrastructure with an emphasis on speed, precision, and sustainability [5][6] Industry Context - The Polaris Forge 1 campus is designed to meet the accelerating demand for AI compute, showcasing the company's capability to deliver critical IT capacity efficiently [3][4] - Applied Digital has been recognized as the Best Data Center in the Americas 2025 by Datacloud, highlighting its leadership in the data center industry [6]

Core Insights - NANO Nuclear Energy Inc. has signed a Feasibility Study Agreement with BaRupOn LLC to evaluate the deployment of multiple KRONOS MMR units to generate 1 GW of nuclear energy at the Liberty American Multi-Sourced Power and Innovation Hub in Texas [1][3][4] - The feasibility study will assess power demand, reactor integration, and site suitability for the KRONOS MMR units [2][6] - BaRupOn anticipates a significant power squeeze due to increasing compute demand, particularly from the tech industry, and is willing to co-invest in the construction of NANO Nuclear's microreactors [3][4] Company Overview - NANO Nuclear is focused on developing advanced nuclear micro modular reactors and clean energy solutions, positioning itself as a key player in the North American advanced reactor market [1][14] - The KRONOS MMR is a high-temperature, gas-cooled microreactor designed for modular deployment, capable of powering large industrial campuses and data centers [7][8] - The collaboration with BaRupOn is seen as a strategic opportunity to address the growing energy needs of high-energy-intensive sectors, particularly in the context of AI and data centers [4][8] Industry Context - The demand for electricity in the tech industry, especially for high-performance computing and data centers, is expected to double within the decade, creating a need for reliable, emission-free power sources [8][21] - The LAMP hub is designed to support advanced manufacturing and AI data centers, highlighting the intersection of energy development and technological innovation [6][13] - The feasibility study represents a significant milestone in NANO Nuclear's roadmap for commercial deployment and could lead to further multi-reactor agreements across the U.S. [11]

Core Points - Monster Beverage Corporation will host an investor meeting on December 2, 2025, to update on business and operations, available via live webcast [1] - The CEO and senior executives will participate in a fireside chat at the Morgan Stanley Global Consumer & Retail Conference on December 3, 2025, also available via live webcast [2] Company Overview - Monster Beverage Corporation is based in Corona, California, and operates primarily through its consolidated subsidiaries, focusing on the development and marketing of energy drinks and other beverages [3] - The company's product range includes various energy drink brands such as Monster Energy®, Java Monster®, and Reign® Total Body Fuel, as well as still and sparkling waters and craft beers [3]

Core Points - Liberty Defense Holdings Ltd. has formed a strategic partnership with Noble IQ to support the installation, training, and maintenance of its HEXWAVE™ threat detection system across the United States [1][2][3] - Noble IQ will provide 24/7 technical support to ensure optimal performance and system uptime for Liberty's customers [2][3] - The partnership aims to enhance customer satisfaction and support Liberty's growth strategy by ensuring professional service and training for HEXWAVE deployments [3] Company Overview - Liberty Defense specializes in AI-based detection solutions for concealed weapons and threats, focusing on high-traffic areas requiring enhanced security [5][6] - The HEXWAVE product utilizes advanced 3D radar imaging technology and is designed for discreet, modular, and scalable protection against both metallic and non-metallic weapons [5][6] - Liberty has also licensed additional technologies, including millimeter wave-based body and shoe scanners, to expand its security solutions portfolio [6] Meeting Notice - An amendment has been made to the Company's Notice of Meeting regarding the date for shareholders of record, now set for November 6, 2025 [4]

Core Insights - The updated three-year results from the FIREFLY-1 trial demonstrate that 77% of patients who entered a treatment-free observation period after OJEMDA treatment remained off therapy for at least 12 months [1][5] - The median time to next treatment (TTNT) following the initiation of OJEMDA exceeded 3.5 years [1][5] - Tovorafenib shows potential as a second-line standard of care for pediatric low-grade glioma (pLGG) [3][4] Trial Results - In the FIREFLY-1 trial, 76 evaluable patients showed an overall response rate of 53% (40/76), with a median duration of response of 19.4 months [3][14] - The median time to response was 5.4 months, and the median progression-free survival was 16.6 months [3][5] - Among 39 patients who entered a treatment-free observation period, the median treatment-free interval was not reached, with minimal tumor rebound observed [5] Safety Profile - No new safety signals were identified in the updated analysis, with common grade 3 or higher adverse events including decreased growth velocity and anemia [6][14] - The most frequently reported adverse reactions (≥30%) included rash, fatigue, and viral infections [14][15] Regulatory Status - Tovorafenib (OJEMDA) is approved by the FDA for pediatric patients aged 6 months and older with relapsed or refractory pLGG harboring a BRAF fusion or rearrangement [7][8] - The drug has received Breakthrough Therapy and Rare Pediatric Disease designations from the FDA [10] Industry Context - Pediatric low-grade glioma is the most common brain tumor in children, with significant unmet medical needs due to the lack of approved treatments targeting BRAF alterations [11][12] - The FIREFLY-1 trial is part of a broader effort to evaluate tovorafenib in pediatric patients with pLGG, highlighting the importance of targeted therapies in this demographic [13][18]

MALVERN, Pa., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced two presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference, taking place December 1-4, 2025 in San Diego, California. The presentations will highlight progress across the Alzheimer’s an ...

Core Viewpoint - Neuphoria Therapeutics Inc. is urging stockholders to vote for its two nominees for the Board of Directors, emphasizing their qualifications and the importance of stability during the ongoing strategic review process [1][2][4]. Group 1: Board Nominees and Voting - Neuphoria is advocating for stockholders to vote "FOR" its nominees, Peter Miles Davies and David Wilson, who possess significant expertise in investment and capital allocation relevant to the company's strategic review [2][8]. - A dissident stockholder, Lynx1 Master Fund LP, has nominated its own candidates, and Neuphoria is urging stockholders to vote "WITHHOLD" on these nominees [3][12]. - The company emphasizes that introducing inexperienced directors could disrupt the strategic review process and negatively impact value creation [11][13]. Group 2: Strategic Review Process - Neuphoria's Board is committed to maximizing value for all stockholders and is conducting a comprehensive review of strategic alternatives with the help of independent financial and legal advisors [4][6]. - The strategic review process is ongoing, with H.C. Wainwright & Co. serving as the financial advisor, and the Board is evaluating various proposals from interested parties [6][7]. - The company believes that maintaining continuity on the Board is critical to successfully completing the strategic review and maximizing value [8][21]. Group 3: Financial Position and Pipeline - Neuphoria has raised capital through its at-the-market program to ensure a strong financial position ahead of anticipated clinical data readouts, which is crucial for negotiating favorable terms with investors [15][16]. - Following a negative data readout from the AFFIRM-1 Phase 3 trial, the company is focused on exploring strategic alternatives and pursuing other pipeline programs [16][24]. - The company’s financial preparedness enhances its credibility and ability to attract high-quality strategic opportunities, thereby maximizing long-term stockholder value [18][20].

Core Insights - Atico Mining Corporation announced positive results from 19 drill holes at the El Roble mine, indicating potential for expanding tonnage and discovering new mineralization [1][2] - The ongoing drilling campaign aims to enhance confidence in the presence of high-grade copper and gold mineralization within and beyond historically defined bodies [2] Exploration Drilling Results - Significant assay results include: - Hole ATDM-061: 8.70m of 11.44% Cu and 14.65 g/t Au - Hole ATDM-037: 6.16m of 13.32% Cu and 2.79 g/t Au - Other notable intercepts range from 1.2m to 16.7m with varying copper and gold grades [1][3] Drilling Program Objectives - The 2025 underground drilling program focuses on defining mineralization zones within the main historic massive sulphide body and exploring for new bodies [4] - The program has completed 885.6 meters of drilling in 2025, continuing from the initial phase that began in early 2023 [4] El Roble Mine Overview - The El Roble mine is a high-grade underground copper and gold mine with a processing capacity of 1,000 tonnes per day, located in Colombia [7] - Proven and Probable reserves are estimated at 1.00 million tonnes with a grade of 3.02% copper and 1.76 g/t gold, with mineralization open at depth and along strike [8] Geological Context - Atico has identified a significant stratigraphic contact over ten kilometers, which is crucial for VMS mineralization, and is currently the focus of surface drilling [9]

Core Insights - Enlivex Therapeutics is set to implement a unique treasury strategy centered around the RAIN prediction markets token, marking it as the first publicly-listed company to do so in the U.S. [1][8] - The company is continuing the clinical development of Allocetra™, a therapy aimed at treating knee osteoarthritis, addressing a significant unmet medical need in a growing market [2][9] - The private placement transaction involves the sale of 212 million ordinary shares at $1.00 per share, yielding approximately $212 million in gross proceeds [3] Company Developments - Enlivex will appoint former Italian Prime Minister Matteo Renzi to its Board of Directors following the private placement [2] - The company plans to utilize the net proceeds from the PIPE transaction to implement the RAIN treasury strategy while maintaining focus on its core business operations [3][5] - The price per share for the private placement represents an 11.5% premium over the previous closing price [2] Industry Context - The prediction markets sector is experiencing significant institutional interest, highlighted by a $2 billion investment in Polymarket and a $300 million financing round for Kalshi [5] - RAIN is described as a fully decentralized predictions and options protocol, allowing users to create and trade custom options on various markets [4] - The market for osteoarthritis treatments is substantial, with over 32.5 million Americans affected and projections indicating that 78 million Americans may have osteoarthritis by 2040 [9]